Coherus Oncology, INC. (CHRS) SEC Filings — 2025
20 SEC filings for Coherus Oncology, INC. (CHRS) in 2025.
Filings
- Coherus Oncology Files 8-K with Financial Data — 8-K · Nov 13, 2025
- Coherus Swings to Profit on UDENYCA Divestiture, LOQTORZI Sales Up — 10-Q · Nov 6, 2025
- Daiichi Sankyo to Acquire Coherus Oncology — 8-K · Sep 8, 2025
- Coherus Oncology Revenue Surges 209% on Toripalimab Sales — 10-Q · Aug 7, 2025
- Coherus Oncology Faces Delisting Concerns — 8-K · Jul 3, 2025
- Coherus Oncology Files 8-K on Shareholder Vote Matters — 8-K · Jun 13, 2025
- Coherus Oncology Files 8-K with Corporate Updates — 8-K · May 30, 2025
- Coherus BioSciences Q1 2025 10-Q Filed — 10-Q · May 12, 2025
- Coherus BioSciences Files DEF 14A for Executive Compensation — DEF 14A · Apr 29, 2025
- Coherus BioSciences CEO Departs, New Interim Officers Appointed — 8-K · Apr 25, 2025
- Coherus BioSciences Director Departs, Officer Compensation Noted — 8-K · Apr 22, 2025
- Coherus BioSciences Completes Asset Acquisition — 8-K · Apr 14, 2025
- Coherus BioSciences Files 8-K with Material Agreement — 8-K · Apr 1, 2025
- Coherus BioSciences Files 2024 10-K — 10-K · Mar 17, 2025
- Coherus BioSciences Files 8-K on Security Holder Vote — 8-K · Mar 13, 2025
- Coherus BioSciences Files 8-K on Financials — 8-K · Mar 10, 2025
- Coherus BioSciences Relocates Principal Executive Offices — 8-K · Mar 4, 2025
- Coherus BioSciences Files Definitive Proxy Statement — DEFA14A · Jan 30, 2025
- Coherus BioSciences Files Proxy Statement — DEFA14A · Jan 14, 2025
- Coherus BioSciences Files 8-K on Financials — 8-K · Jan 13, 2025